Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00589706 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Adjuvant Use of Anti-Epidermal Growth Factor Receptor EGFR-425 in High Grade Gliomas
A Phase 2 study of Gliomas, sponsored by Drexel University College of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT00589706 is a Phase 2 study of Gliomas that has completed, run by Drexel University College of Medicine. The registered enrollment target is 11 participants, below the 43-participant average among 3 other Gliomas trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00589706, a Phase 2 study of Gliomas, has completed, sponsored by Drexel University College of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
Data from the wistar institute indicated that this anti-body labeled with iodine-125 would localized in the tumor cells of high grade gliomas of the brain. the project combines surgery, radiation therapy, chemotherapy with the labeled antibody in a prospective phase II trial in this disease entity.
Conditions Studied
Interventions
- DRUG MAb-425
Study Locations (1)
Pennsylvania
- Hahneman Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 1985-01 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00589706
The ClinicalTrials.gov registry entry for NCT00589706 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 43-participant average among 3 other Gliomas trials with a reported enrollment target (74% lower). The listed sponsor is Drexel University College of Medicine, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gliomas appearing as the primary indexed condition, and to 1 intervention - of which MAb-425 is the first listed.
NCT00589706 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00589706 about?
NCT00589706 is a clinical study titled "A Phase II Study of Adjuvant Use of Anti-Epidermal Growth Factor Receptor EGFR-425 in High Grade Gliomas". Data from the wistar institute indicated that this anti-body labeled with iodine-125 would localized in the tumor cells of high grade gliomas of the brain. the project combines surgery, radiation therapy, chemotherapy with the labeled antibody in a prospective phase II trial in this disease entity.
What is the current status of trial NCT00589706?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 1985-01. Estimated completion is 2012-12.
What conditions does trial NCT00589706 study?
This clinical trial studies the following conditions: Gliomas.
What interventions are being tested in trial NCT00589706?
The interventions under investigation include: MAb-425 (DRUG).
Who is sponsoring clinical trial NCT00589706?
This trial is sponsored by Drexel University College of Medicine, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00589706 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gliomas
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.